失调
医学
临床试验
疾病
免疫系统
重症监护医学
肠道菌群
肝病
临床实习
细菌易位
生物信息学
免疫学
内科学
生物
染色体易位
生物化学
家庭医学
基因
作者
Gokulapriya Ramachandran,Biju Pottakkat
出处
期刊:Journal of Medicinal Food
[Mary Ann Liebert]
日期:2024-04-03
标识
DOI:10.1089/jmf.2023.k.0129
摘要
An increased incidence of liver diseases has been observed in recent years and is associated with gut dysbiosis, which causes bacterial infection, intestinal permeability, and further leads to disease-related complications. Probiotics, active microbial strains, are gaining more clinical importance due to their beneficial effect in the management of many diseases, including liver diseases. Clinical scenarios show strong evidence that probiotics have efficacy in treating liver diseases due to their ability to improve epithelial barrier function, prevent bacterial translocation, and boost the immune system. Moreover, probiotics survive both bile and gastric acid to reach the gut and exert their health benefit. Evidence shows that probiotics are a promising approach to prevent several complications in clinical practice. Herein, we discuss the recent evidence, challenges, and appropriate use of probiotics in managing advanced liver diseases, which may have an impact on future therapeutic strategies. Furthermore, the superior effect of strain-specific probiotics and their efficacy and safety in managing liver diseases are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI